Pharmacology, Toxicology and Pharmaceutical Science
Opiate
100%
Receptor
89%
Opiate Receptor
87%
Buprenorphine
66%
Narcotic Antagonist
48%
Nociceptin
44%
Naltrexone
32%
μ-Opioid Receptor
32%
Partial Agonist
30%
Kappa Opiate Receptor
27%
Morphine
26%
Imidazoline
24%
Binding Site
24%
Opiate Agonist
23%
Antinociception
21%
Rhesus Monkey
20%
Naloxone
19%
Disease
18%
RGS Protein
17%
Analgesic Agent
15%
Mouse Model
15%
Kappa Antagonists
14%
Mu Opiate Receptor Agonist
13%
Opiate Peptide
13%
Antidepressant
12%
Mu Opiate Receptor Antagonist
12%
Carbon 11
11%
Ether Derivative
11%
Structure Activity Relationship
11%
Cannabinoid Receptor Agonist
10%
Behavioral Effect
10%
Diamorphine
10%
Receptor Antagonist
9%
Haplorhini
9%
Tracer
9%
2 (2 Imidazolin 2 Yl)quinoline
9%
3,4 Dichloro N Methyl N [2 (1 Pyrrolidinyl)cyclohexyl]benzeneacetamide
9%
Clocinnamox
8%
Duragesic
8%
Morphinone
8%
Ethanol
8%
Respiration Depression
8%
Diarrhea
8%
Imine
8%
Guanine Nucleotide Binding Protein
8%
Receptor Agonist
8%
Opioid Overdose
7%
Naltrindole
7%
Imidazoline Receptor
7%
Delta Opiate Receptor Agonist
7%
Neuroscience
Opiate
60%
Receptor
52%
Buprenorphine
22%
Imidazoline
22%
In Vivo
21%
Naltrexone
20%
Binding Site
19%
Antidepressant
18%
Receptor Agonists
18%
In Vitro
17%
Nociceptin
17%
Agonist
16%
μ-Opioid Receptor
14%
Kappa Opiate Receptor
14%
Narcotic Antagonist
12%
Behavior (Neuroscience)
12%
Morphine
11%
Kappa Antagonists
11%
Opioid Peptide
8%
Naltrindole
8%
Behavioral Effect
7%
Meta-Analysis
6%
Imidazoline Receptor
6%
Protein Binding
6%
Heroin
6%
Drug Abuse
6%
Positron Emission Tomography
5%
Receptor Antagonist
5%
Radioligand
5%
Medicine and Dentistry
Buprenorphine
19%
Naltrexone
18%
Opioid Receptor
15%
Opiate
11%
Receptor
11%
Opiate Antagonist
8%
Antinociception
8%
Morphine
8%
Antidepressant
7%
μ-Opioid Receptor
7%
Disease
7%
Kappa Opiate Receptor Antagonist
6%
Partial Agonist
6%
Respiration Depression
6%
Conditioned Place Preference
5%
Opiate Agonist
5%
Cannabinoid
5%
Guanine Nucleotide Binding Protein
5%
